131I-MIBG--a new agent in diagnosis and treatment of pheochromocytoma.
The newly developed radiopharmaceutical, 131I-metaiodobenzylguanidine (131I-MIBG), has been shown to be efficacious for the location of intra- and extra-adrenal, primary pheochromocytomas and metastatic, malignant pheochromocytomas (11.4% false-negative and 1.8% false-positive in patients with proven pheochromocytomas). Preliminary experience in selected patients with malignant pheochromocytoma suggest that therapy using large doses of 131I-MIBG results in partial tumor regression and improvement in catecholamine hypersecretion in some cases.
D019797:3-Iodobenzylguanidine; D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D000311:Adrenal Glands / Q000000981:diagnostic imaging; D002395:Catecholamines / Q000378:metabolism; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D007462:Iodobenzenes / Q000627:therapeutic use; D010673:Pheochromocytoma / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D011877:Radionuclide Imaging
D002395:Catecholamines; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine